Author/Authors :
Azarkar, Zohreh Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran , Ebrahimzadeh, Azadeh nfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran , Sharifzadeh, Gholamreza nfectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran , Ziaee, Masood Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran , Fereidouni, Mohammad Asthma, Allergy and Immunology Research Center, Medical Sciences of University, Birjand, Iran , Taheri, Fatemeh Asthma, Allergy and Immunology Research Center, Medical Sciences of University, Birjand, Iran
Abstract :
Background: In Iran since 1992, hepatitis B vaccination was a part of the national
vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis
B. The aim of this study was to evaluate the long – term persistence of immunity.
Methods: This cross-sectional analytical study was conducted on children and adolescents
aged between 6-18 years in Birjand, who received a three – dose hepatitis B vaccination in
accordance with the national immunization program. No students were infected with
hepatitis B. Antibody titer higher than10 IU/L was considered positive.
Results: A total of 530 patients (307 boys and 223 girls) were recruited for the study of
which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean
(GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4%
of the boys and 59.6% of the girls. A significant difference in antibody titers was observed
in terms of gender and according to the time elapsed since the last vaccination. Antibody
titer in children older than 13 years had passed since their last vaccination and was
significantly less than those children younger than thirteen years old had passed since their
vaccination logistic regression analysis showed that the only predictive factor of anti-HBS
low titer (<10 IU/L) is elapsed time of vaccination.
Conclusions: Based on results of this study, hepatitis B vaccine has created a good level of
protection in 44% of the adolescents after 17 years.